GUMDROP : Multimodaliaty Therapy incl. docetaxel, sunitinib, and external beam radiotherapy, for Recurrent High Risk Prostate Cancer. A Phase II Study

Created by Channing Paller, last modified on Apr 14, 2012

Description:

Radical prostatectomy w/i 3 yrs (Gleason score 7-10); PSA =2.0 ng/ml and =0.2 ng/ml; rising PSA without evidence of metastatic disease; NO prior systemic or biologic therapy

Link:

http://clinicaltrials.gov/ct2/show/NCT00734851

 

Site:

Johns Hopkins Hospital

Principal Investigator:

Dr. Phuoc Tran